<DOC>
	<DOC>NCT02378961</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and efficacy of GS-9857 plus sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Individuals with chronic HCV infection HCV RNA â‰¥10^4 IU/mL at screening HCV genotypes 2, 3, 4, 5, or 6 Cirrhosis determination; a liver biopsy may be required Screening laboratory values within defined thresholds Use of two contraception methods if female of childbearing potential or sexually active male Pregnant or nursing female Current or prior history of hepatic decompensation Hepatocellular carcinoma (HCC) or other clinically significant malignancy Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>